Keytruda SC
Various Cancers (SC Formulation)
Pre-registrationActive (Licensed to Merck)
Key Facts
Indication
Various Cancers (SC Formulation)
Phase
Pre-registration
Status
Active (Licensed to Merck)
Company
About Alteogen
Alteogen's mission is to develop innovative biobetter and biosimilar pharmaceuticals through its proprietary technology platforms. The company achieved a watershed financial performance in 2025, with consolidated revenue of KRW 2.159 trillion (approx. $1.6B USD) and net profit of KRW 1.443 trillion, driven by its platform-centric business model of licensing and profit-sharing. Its strategy focuses on expanding its technology moat through R&D and securing global partnerships to commercialize its pipeline, while transitioning to a mature, shareholder-returning entity.
View full company profile